{"id":389226,"date":"2020-11-30T02:13:24","date_gmt":"2020-11-30T07:13:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389226"},"modified":"2020-11-30T02:13:24","modified_gmt":"2020-11-30T07:13:24","slug":"genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/","title":{"rendered":"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 <\/strong><br \/>\n        <strong>\u2013 GENFIT (Nasdaq and Euronext: GNFT)<\/strong> a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that:<\/p>\n<ul type=\"disc\">\n<li>the reverse book building process for the partial buyback of GENFIT\u2019s 6,081,081 convertible bonds maturing in October 2022 (\u201c<strong>OCEANEs<\/strong>\u201d) achieved satisfactory results and ended on November 27, 2020 (COB) as planned;<br \/>\u00a0<\/li>\n<li>the Bond Purchase Agreements from investors having tendered their OCEANEs will be collected as quickly as possible and once the process is completed, GENFIT will communicate the final results of the partial buyback.<\/li>\n<\/ul>\n<p>\n        \n      <\/p>\n<p>\n        <strong>ABOUT GENFIT<\/strong>\n      <\/p>\n<p align=\"justify\">GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in a Phase 3 clinical trial evaluating elafibranor in patients with primary biliary cholangitis (PBC). As part of GENFIT\u2019s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4\u2122, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH.\u00a0 NIS4\u2122 technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4\u2122 technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext\u2019s regulated market in Paris (Nasdaq and Euronext: GNFT). <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aG6h1y_UxY5rLmmFW7mK2sr3wIceDpvp5pZHBoVC9DTTQUQW8G2ujhomH26j1vAxB2M31y0kK5hAa0dP0w4rbA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.genfit.com<\/a><\/u><\/p>\n<p align=\"justify\">\n        <strong>FORWARD LOOKING STATEMENTS<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements regarding our capacity to renegotiate the terms of our OCEANEs and that the final terms of this proposal will be approved by the shareholders\u2019 general meeting and general meeting of OCEANEs\u2019 holders. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements.\u00a0 Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company\u2019s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company\u2019s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company\u2019s public filings with the French Autorit\u00e9 des march\u00e9s financiers (\u201cAMF\u201d), including those listed in Section 4 \u201cMain Risks and Uncertainties\u201d of the Company\u2019s 2019 Universal Registration Document filed with the AMF on May 27, 2020 under n\u00b0 D.20-0503, which is available on GENFIT\u2019s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s 20-F dated May 27, 2020. In addition, even if the Company\u2019s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.\u00a0 These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. <\/p>\n<p align=\"justify\">\n        <strong>CONTACT<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>GENFIT<\/strong> | Investors<\/p>\n<p align=\"justify\">Naomi EICHENBAUM \u2013 Investor Relations | Tel: +1 (617) 714 5252 | <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pwaf3K3nnyrQqH4Uv6kcGxCF51Qk1u31XxpufAt0jku2DIhhtBI0s1Xjk3nLOdZK3p0TVKp-vIwWfMVqmWpkp1ZTu4fd2pCPxfaqMqbQjsk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@genfit.com<\/a><\/u><\/p>\n<p align=\"justify\">\n        <strong>PRESS RELATIONS <\/strong>| Media<\/p>\n<p align=\"justify\">H\u00e9l\u00e8ne LAVIN \u2013 Press relations | Tel: +333 2016 4000 | <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3DrQurjCY3rslm9cZrD97OByZx921FJs-4Ei9BI5ADr_CLuJbySbhX4rPT0Ty3dpGqJi1CdaPsPonWAwajI7foXRgl67q3B14x9fz6tPJno=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">helene.lavin@genfit.com<\/a><\/u><\/p>\n<p>\n        <strong>GENFIT<\/strong> | 885 Avenue Eug\u00e8ne Avin\u00e9e, 59120 Loos &#8211; FRANCE | +333 2016 4000 | www.genfit.com\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  <\/p>\n<p \/>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/28996af2-7ffa-4098-8927-3409ae9e5cff\" rel=\"noopener noreferrer\">GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer<\/a>\n        <\/li>\n<\/ul>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/bdac7c81-541d-4ff5-8538-0551041fb63e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 \u2013 GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that: the reverse book building process for the partial buyback of GENFIT\u2019s 6,081,081 convertible bonds maturing in October 2022 (\u201cOCEANEs\u201d) achieved satisfactory results and ended on November 27, 2020 (COB) as planned;\u00a0 the Bond Purchase Agreements from investors having tendered their OCEANEs will be collected as quickly as possible and once the process is completed, GENFIT will communicate the final results of the partial buyback. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389226","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 \u2013 GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that: the reverse book building process for the partial buyback of GENFIT\u2019s 6,081,081 convertible bonds maturing in October 2022 (\u201cOCEANEs\u201d) achieved satisfactory results and ended on November 27, 2020 (COB) as planned;\u00a0 the Bond Purchase Agreements from investors having tendered their OCEANEs will be collected as quickly as possible and once the process is completed, GENFIT will communicate the final results of the partial buyback. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver &hellip; Continue reading &quot;GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T07:13:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer\",\"datePublished\":\"2020-11-30T07:13:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/\"},\"wordCount\":701,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/\",\"name\":\"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==\",\"datePublished\":\"2020-11-30T07:13:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/","og_locale":"en_US","og_type":"article","og_title":"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer - Market Newsdesk","og_description":"Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 \u2013 GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that: the reverse book building process for the partial buyback of GENFIT\u2019s 6,081,081 convertible bonds maturing in October 2022 (\u201cOCEANEs\u201d) achieved satisfactory results and ended on November 27, 2020 (COB) as planned;\u00a0 the Bond Purchase Agreements from investors having tendered their OCEANEs will be collected as quickly as possible and once the process is completed, GENFIT will communicate the final results of the partial buyback. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver &hellip; Continue reading \"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T07:13:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer","datePublished":"2020-11-30T07:13:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/"},"wordCount":701,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/","name":"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==","datePublished":"2020-11-30T07:13:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0Mjk1OCM0MDA4MzAyMjIjMTAxMTI2OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genfit-announces-satisfactory-preliminary-results-of-its-oceanes-partial-buyback-offer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GENFIT announces satisfactory preliminary results of its OCEANEs\u2019 partial buyback offer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389226"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389226\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}